Landos Biopharma Inc. announced a $60m series B venture capital financing on 13 August to keep the development plan for its rapidly progressing oral drug candidate BT-11 for inflammatory bowel disease (IBD) moving forward.
Phase II clinical trials in ulcerative colitis (UC) and Crohn's disease are underway after a Phase I study in healthy volunteers confirmed that the first-in-class lanthionine synthetase C-like 2 (LANCL2) inhibitor was safe enough to test
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?